GLP-1 Weight Loss Medications in 2026: Ozempic, Wegovy, Mounjaro & Zepbound Compared
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-04-10 · 12 min read
A clinical look at GLP-1 receptor agonists for weight loss — efficacy, side effects, cost, and how semaglutide and tirzepatide are reshaping obesity care in 2026.
The GLP-1 Revolution in Weight Loss
GLP-1 receptor agonists have transformed obesity medicine. By mimicking the gut hormone glucagon-like peptide-1, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow gastric emptying, reduce appetite, and improve insulin sensitivity — producing 15-22% average body weight loss in clinical trials.
Head-to-Head: 2026 Data
- Wegovy (semaglutide 2.4mg): ~15% body weight reduction at 68 weeks (STEP trials)
- Zepbound (tirzepatide 15mg): ~22.5% body weight reduction at 72 weeks (SURMOUNT-1)
- Retatrutide (Eli Lilly, Phase 3): Preliminary data showing 24%+ weight loss
Benefits Beyond the Scale
New 2026 cardiovascular outcome data (SELECT trial follow-up) confirms GLP-1s reduce major adverse cardiac events by 20% and improve obstructive sleep apnea severity by up to 63% (SURMOUNT-OSA). For patients on CPAP or BiPAP, weight loss often reduces required pressure settings and may even resolve mild apnea.
Side Effects & Considerations
Nausea, constipation, and pancreatitis risk remain the most common concerns. New FDA labeling in 2026 also requires monitoring for euglycemic ketoacidosis and gastroparesis.
If sleep apnea is part of your weight-related health picture, pair medical weight loss with proper CPAP therapy — many patients can downgrade pressure settings as they lose weight.